News | 4BIO Capital | London | Page 11 of 11

top of page

NEWSROOM

Dec 20, 2017

4BIO Capital participates in $110M Series B Financing of Orchard Therapeutics

4BIO Capital participates in $110M Series B Financing of Orchard Therapeutics

Dec 19, 2017

FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl)

FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl)

11

bottom of page